Revolutionary approach

DeuteRx has pioneered Deuterium-Enabled Chiral Switching (DECS) to stabilize and characterize the preferred enantiomers for the racemic active ingredients of >13 marketed drugs.
Numerous drugs are still being developed and marketed with racemic active ingredients because their enantiomers interconvert. Representative drugs include Actos® (pioglitazone), Aricept® (donepezil), Wellbutrin® (bupropion), and Revlimid® (lenalidomide). Replacing the exchangeable hydrogen at the chiral center with deuterium enables stabilization and characterization of the single, preferred enantiomer with new composition of matter patent protection and an expedited path to market. DRX-065, the deuterium-stabilized R-enantiomer of pioglitazone, is a mitochondrial function modulator without the PPAR-gamma agonist activity of Actos® and its associated side effects that are due to S-pioglitazone.

Creating Improved NCEs
with New IP &
Speed to Market